Table 1 Patient characteristics

Total number of patients

554

Median follow-up time

7.4 Years

Median age at diagnosis (range)

57.5 Years (22–85)

 ≥ 50 years = 402

 < 50 years = 152

Race/ethnicity

White = 500, Black = 29

Hispanic (White or Other) = 14, Asian = 6

Multiracial/Other = 10, Unknown = 8

Ki67(%)

Low (≤ 15%) = 104, High (≥ 15%) = 161

Tumor stage at Dx

T = 292, T2 = 201, T3 = 41, T4 = 8, Tis = 8

Gender

F = 542, M = 12

Molecular subtype

TN = 74, ER/PR + ;HER2 +  = 69

ER/PR + ;HER2- = 362, ER/PR-;HER2 +  = 21

ER/PR + , unknown Her2 status = 4

Nodal status

N0 = 320, N +  = 230

Vital status

Alive = 394, Deceased = 116

Unknown/Lost to follow up = 44

Subtype by FISH or IHC

Her2 Type = 12, Luminal = 196

Luminal A = 161, Luminal B = 127

Triple negative = 85

Paired samples (Normal)

Yes = 554

BRCA1-mutation

Yes = 8, no = 546

BRCA2-mutation

Yes = 12, no = 542

Tumor histology

Invasive ductal adenocarcinoma = 473

invasive lobular carcinoma = 52

mixed carcinoma = 5, Other = 2

Menopausal status

Yes = 244, no = 36

Therapy

Any chemotherapy = 390

Neoadjuvant chemotherapy = 75

First site of distant metastasis

Visceral = 14, bone = 15, brain/CNS = 2

Skin, other = 5, multiple = 24